BidaskClub Upgrades Synergy Pharmaceuticals (SGYP) to Sell
BidaskClub upgraded shares of Synergy Pharmaceuticals (NASDAQ:SGYP) from a strong sell rating to a sell rating in a research note published on Wednesday.
SGYP has been the subject of several other reports. HC Wainwright set a $7.00 price target on shares of Synergy Pharmaceuticals and gave the company a buy rating in a research report on Monday, December 4th. Cantor Fitzgerald restated a buy rating and issued a $10.00 price target on shares of Synergy Pharmaceuticals in a research report on Thursday, January 25th. Oppenheimer cut shares of Synergy Pharmaceuticals from an outperform rating to a market perform rating in a research report on Thursday, January 4th. Canaccord Genuity set a $13.00 price target on shares of Synergy Pharmaceuticals and gave the company a buy rating in a research report on Sunday, November 12th. Finally, BTIG Research restated a buy rating and issued a $7.00 price target on shares of Synergy Pharmaceuticals in a research report on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. Synergy Pharmaceuticals currently has a consensus rating of Hold and an average target price of $8.28.
Synergy Pharmaceuticals (SGYP) traded down $0.06 during mid-day trading on Wednesday, reaching $2.05. 4,920,100 shares of the company were exchanged, compared to its average volume of 7,243,121. The company has a debt-to-equity ratio of -68.13, a quick ratio of 3.88 and a current ratio of 4.26. Synergy Pharmaceuticals has a twelve month low of $1.68 and a twelve month high of $6.45. The firm has a market cap of $505.65, a PE ratio of -1.77 and a beta of 1.13.
About Synergy Pharmaceuticals
Synergy Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s product candidates include TRULANCE (plecanatide) and dolcanatide. The Company is engaged in the discovery, research and development efforts around analogs of uroguanylin for the treatment of GI diseases and disorders.
Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.